136 related articles for article (PubMed ID: 34116945)
1. Decisional tool for cost of goods analysis of bioartificial liver devices for routine clinical use.
Mendonça da Silva J; Stamatis C; Chalmers SA; Erro E; Selden C; Farid SS
Cytotherapy; 2021 Aug; 23(8):683-693. PubMed ID: 34116945
[TBL] [Abstract][Full Text] [Related]
2. End-to-end continuous bioprocessing: Impact on facility design, cost of goods, and cost of development for monoclonal antibodies.
Mahal H; Branton H; Farid SS
Biotechnol Bioeng; 2021 Sep; 118(9):3468-3485. PubMed ID: 33792918
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic cell therapy bioprocess economics and optimization: downstream processing decisions.
Hassan S; Simaria AS; Varadaraju H; Gupta S; Warren K; Farid SS
Regen Med; 2015; 10(5):591-609. PubMed ID: 26237703
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologies.
Simaria AS; Hassan S; Varadaraju H; Rowley J; Warren K; Vanek P; Farid SS
Biotechnol Bioeng; 2014 Jan; 111(1):69-83. PubMed ID: 23893544
[TBL] [Abstract][Full Text] [Related]
5. Development of a bioreactor based on magnetically stabilized fluidized bed for bioartificial liver.
Deng F; Chen L; Zhang Y; Zhao S; Wang Y; Li N; Li S; Guo X; Ma X
Bioprocess Biosyst Eng; 2015 Dec; 38(12):2369-77. PubMed ID: 26391509
[TBL] [Abstract][Full Text] [Related]
6. Progress in bioreactors of bioartificial livers.
Yu CB; Pan XP; Li LJ
Hepatobiliary Pancreat Dis Int; 2009 Apr; 8(2):134-40. PubMed ID: 19357025
[TBL] [Abstract][Full Text] [Related]
7. A New Fluidized Bed Bioreactor Based on Diversion-Type Microcapsule Suspension for Bioartificial Liver Systems.
Lu J; Zhang X; Li J; Yu L; Chen E; Zhu D; Zhang Y; Li L
PLoS One; 2016; 11(2):e0147376. PubMed ID: 26840840
[TBL] [Abstract][Full Text] [Related]
8. Human pluripotent stem cell-derived products: advances towards robust, scalable and cost-effective manufacturing strategies.
Jenkins MJ; Farid SS
Biotechnol J; 2015 Jan; 10(1):83-95. PubMed ID: 25524780
[TBL] [Abstract][Full Text] [Related]
9. A new bioartificial liver using porcine hepatocyte spheroids in high-cell-density suspension perfusion culture: in vitro performance in synthesized culture medium and in 100% human plasma.
Sakai Y; Naruse K; Nagashima I; Muto T; Suzuki M
Cell Transplant; 1999; 8(5):531-41. PubMed ID: 10580347
[TBL] [Abstract][Full Text] [Related]
10. A new concept of bioartificial liver based on a fluidized bed bioreactor.
Doré E; Legallais C
Ther Apher; 1999 Aug; 3(3):264-7. PubMed ID: 10427626
[TBL] [Abstract][Full Text] [Related]
11. Evaluating end-to-end continuous antibody manufacture with column-free capture alternatives from economic, environmental, and robustness perspectives.
Neves CPG; Coffman JL; Farid SS
Biotechnol Prog; 2024 Jan; ():e3427. PubMed ID: 38289674
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a bioartificial liver device with fluidized bed bioreactors hosting alginate-encapsulated hepatocyte spheroids.
Figaro S; Pereira U; Rada H; Semenzato N; Pouchoulin D; Legallais C
Annu Int Conf IEEE Eng Med Biol Soc; 2015 Aug; 2015():1335-8. PubMed ID: 26736515
[TBL] [Abstract][Full Text] [Related]
13. A clinical-scale BioArtificial Liver, developed for GMP, improved clinical parameters of liver function in porcine liver failure.
Selden C; Bundy J; Erro E; Puschmann E; Miller M; Kahn D; Hodgson H; Fuller B; Gonzalez-Molina J; Le Lay A; Gibbons S; Chalmers S; Modi S; Thomas A; Kilbride P; Isaacs A; Ginsburg R; Ilsley H; Thomson D; Chinnery G; Mankahla N; Loo L; Spearman CW
Sci Rep; 2017 Nov; 7(1):14518. PubMed ID: 29109530
[TBL] [Abstract][Full Text] [Related]
14. Bioartificial liver system based on choanoid fluidized bed bioreactor improve the survival time of fulminant hepatic failure pigs.
Lv G; Zhao L; Zhang A; Du W; Chen Y; Yu C; Pan X; Zhang Y; Song T; Xu J; Chen Y; Li L
Biotechnol Bioeng; 2011 Sep; 108(9):2229-36. PubMed ID: 21455934
[TBL] [Abstract][Full Text] [Related]
15. Key challenges to the development of extracorporeal bioartificial liver support systems.
Zhao LF; Pan XP; Li LJ
Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):243-9. PubMed ID: 22672816
[TBL] [Abstract][Full Text] [Related]
16. Fabrication and in vitro evaluation of a packed-bed bioreactor based on an optimum two-stage culture strategy.
Liu W; Hu D; Gu C; Zhou Y; Tan WS
J Biosci Bioeng; 2019 Apr; 127(4):506-514. PubMed ID: 30322683
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of hydromechanical and functional properties of diversion-type microcapsule-suspension bioreactor for bioartificial liver.
Lu J; Zhu D; Li L
Int J Artif Organs; 2022 Mar; 45(3):309-321. PubMed ID: 35034506
[TBL] [Abstract][Full Text] [Related]
18. Increased hepatic functionality of the human hepatoma cell line HepaRG cultured in the AMC bioreactor.
Nibourg GA; Hoekstra R; van der Hoeven TV; Ackermans MT; Hakvoort TB; van Gulik TM; Chamuleau RA
Int J Biochem Cell Biol; 2013 Aug; 45(8):1860-8. PubMed ID: 23770120
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the fluidized bed bioreactor as an external bioartificial liver.
Figaro S; Pereira U; Rada H; Semenzato N; Pouchoulin D; Paullier P; Dufresne M; Legallais C
Int J Artif Organs; 2017 May; 40(4):196-203. PubMed ID: 28362045
[TBL] [Abstract][Full Text] [Related]
20. Process economics evaluation of cell-free synthesis for the commercial manufacture of antibody drug conjugates.
Stamatis C; Farid SS
Biotechnol J; 2021 Apr; 16(4):e2000238. PubMed ID: 33231912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
